Chemosensitive response prior to transplantation has been shown to be most significant for survival post transplant. To estimate toxicity of a dose-intensive regimen that was to improve chemosensitive response rate, 15 patients with primary refractory lymphoma were enrolled in dose escalation of pre-transplant salvage chemotherapy. The first cycle had a fixed dose of ifosfa- 
Survival of patients with lymphoma treated with autologous stem cell transplantation (ASCT) is influenced by response to pre-transplant salvage therapy. For patients with aggressive non-Hodgkin's lymphoma (NHL) at relapse, sensitivity to standard-dose salvage chemotherapy has been shown to be the most important variable for survival post transplant.
1-2 Pre-transplant disease status of patients with Hodgkin's disease (HD) at first relapse, reflecting sensitivity to chemotherapy, has been shown to be an important prognostic factor for survival after ASCT. [3] [4] [5] Likewise, primary refractory patients with aggressive non-Hodgkin's lymphoma unresponsive to secondary therapy had a poor outcome with a median duration of survival of 6 months and no measurable long-term event-free survival. 6, 7 In the current study of dose escalation in patients with primary refractory lymphoma, a maximum tolerated dose of both ifosfamide and mitoxantrone was sought, before testing the hypothesis that dose-intense salvage chemotherapy increases remission rates prior to transplantation. After the intensive salvage treatment, patients went on to receive ablative therapy with transplantation. Dose escalation of ifosfamide and mitoxantrone was based on the linear dose-response curve in the therapeutic range and nonoverlapping toxicity. 8, 9 Peripheral blood stem cells (PBSC) harvested immediately before the second cycle were used to support two subsequent cycles of treatment to reduce the extent of hematologic toxicity, thereby allowing timely administration of therapy without delay, and later for transplantation. [10] [11] [12] In the present report, we describe toxicities and preliminary response data of the 15 patients.
Patients and methods

Patients
The study was conducted between June 1997 and June 2000, and the patients were followed to December 2000. Patients with either NHL or HD were eligible if they failed to achieve complete remission on induction therapy. The institutional review board of the College of Medicine, the University of Iowa, approved the study and all patients Table 2 for dose escalation.
gave written informed consent at the time of study entry. Eligibility included age between 17 and 60 years old; performance score у50%; diffusion capacity Ͼ60%, FEV 1 Ͼ1.5 l, or PaO 2 Ͼ60 mmHg; left ventricular ejection fraction Ͼ55%; serum creatinine Ͻ1.5 times normal; bilirubin or transaminases Ͻ3 times normal not related to tumor; cumulative dose of doxorubicin Ͻ300 mg/m 2 ; no prior therapy with ifosfamide or mitoxantrone containing regimen(s); no evidence of disease in marrow or blood; no active infection.
Treatment regimen (Tables 1 and 2)
Three cycles of therapy were planned at 4-week intervals or sooner if platelets increased to у75 ϫ 10 . Patients received three courses of therapy at the same dose level for each course. Toxicities were graded using the National Cancer Institute common toxicity criteria. Dose limiting toxicity (DLT) was defined if grade 4 non-hematologic toxicity occurred, the platelet count Ͻ75 ϫ 10 9 /l or ANC Ͻ2 ϫ 10 9 /l in 4 weeks after each cycle. Dose escalation and patient accrual followed a standard phase I study design. Cohorts of three patients were enrolled at each dose level. If no patients in a cohort experienced DLT during a 4-week observation period, the dose was escalated and the next cohort was accrued. If one of three patients experienced DLT, a second cohort of three was added at the same dose level. If two patients experienced a DLT at the same dose level, no further patients were treated at the dose level and an additional cohort of three patients was entered at the previous dose level. Once the maximum tolerated dose (MTD) was established, additional patients could be entered to define toxicity further at this dose level. If a patient who experienced DLT recovered fully from the toxicity, the patient could resume therapy at the previous level. Patients who did not recover fully from DLT in 4 weeks were taken off study.
Peripheral blood stem cells and supportive care
PBSC were mobilized when patients were recovering from the first cycle, with a daily granulocyte colony-stimulating factor (G-CSF) at 10 g/kg. PBSC of 9 ϫ 10 6 CD34 ϩ cells/kg of patient's ideal body weight were collected. Apheresed products were cryopreserved as three separate aliquots, with Ͼ3 ϫ 10 6 CD34 ϩ cells/kg per each. PBSC were infused on day 6 of both the second and third cycles. The remaining aliquot was used for autologous transplantation.
Prophylactic ofloxacin 400 mg/day was used during neutropenia. Sulfamethoxazole 800 mg-trimethoprim 160 mg twice a day and itraconazole 200 mg twice a day were also given for 10 days of each cycle. G-CSF was started day 10 of each cycle until the ANC Ͼ2 ϫ 10 9 /l. Both hemoglobin and platelets were maintained at у10 g/dl and у10 ϫ 10 9 /l, respectively. All blood products were filtered and irradiated to 3000 cGy.
Stem cell transplantation
Transplantation was done within 4 weeks after the last cycle of therapy. The BVAC regimen for ASCT was administered as previously described: 
Response evaluation and survival
Response was evaluated by the methods of Miller et al 15 and Cheson et al. 16 Since all events led to death, resulting in almost identical overall survival and event-free survival, only the event-free survival was presented, calculated by the product limit estimate of the Kaplan-Meier method. Events were defined as death from any cause, or relapse in patients who survived the first 28 days after the transplant.
Results
Patients and dose escalation
Patient characteristics are shown in Table 3 . The median age was 37 years (range, 20 to 56 years) and the median Karnofsky performance score at study entry was 70% (range, 50% to 80%). All patients received the first two cycles of therapy. Four patients did not receive the third cycle: two because of progressive disease (one diffuse large B cell lymphoma (DLCL), one HD); one because of acute renal failure at dose level 3; one because of depression. Three patients completed dose level 1. At dose level 2, six patients were initially accrued because of one episode of grade 3 central nervous system toxicity. At dose level 3, 
Non-hematologic toxicities
One patient developed oliguric acute renal failure at dose level 3, after ifosfamide 15 g/m 2 was concurrently given with vancomycin and gentamicin for a wound infection. His initial renal function was normal with a serum creatinine of 0.8 mg%. No patients at dose level 2 experienced Ͼgrade 2 genitourinary toxicities except for three cases of a mild increase in creatinine and three cases of brief microscopic hematuria. Nine patients (60%) suffered from grades р3 mucositis. The median duration of mucositis was 5 days (range, 2 to 13 days). No patients experienced hepatobiliary toxicity. One patient (7%) developed grade 3 toxicity of the nervous system with ataxia and disorientation at dose level 2. Two patients (13%) experienced mild to moderate parasthesia and mild hearing loss. There were no cases of cardiopulmonary toxicity prior to transplantation.
Hematologic toxicity and infection
The median duration of ANC Ͻ0.5 ϫ 10 9 /l at dose level 1 was 4 days (range, 4-6 days) after the first cycle; 7 days after both second and third cycles (range, 6-12 days; 6-7 days, respectively). The median duration of platelet counts Ͻ20 ϫ 10 9 /l was 8 days (range, 3-15 days) after the second and third cycles. The median time to an ANC Ͼ2 ϫ 10 9 /l after infusion of blood stem cells was 13 days (range, 8-21 days); the median time for a platelet to increase to Ͼ75 ϫ 10 9 /l was 22 days (range, 18-26 days). Eight of 41 cycles of therapy (20%) were complicated by infectious episodes. One patient developed a fatal bilateral pneumonia with Staphylococcus aureus during neutropenia after the third cycle at dose level 3. There were no cases of invasive fungal infection.
Response
Eleven patients (73%) completed three cycles of therapy. Five patients (33%) achieved complete remission (CR) and five (33%) had partial remission (PR), with an overall response rate of 66% by the intent-to-treat principle. Three patients with DLCL, and two with HD had a CR. Two with HD, one with mantle cell lymphoma and two with DLCL had a PR. At dose level 1, there was one CR, one PR and one progressive disease; at level 2, three CR, four PR, two progressive disease; at level 3, one CR and two not evaluated for response because of episodes of DLT.
Transplant therapy
Thirteen patients underwent transplantation. Nine patients underwent ablative therapy with the BVAC regimen and ASCT. Two patients died of multi-organ failure on day 13 and 38 of the transplant, respectively. Two patients died of idiopathic pneumonia syndrome (IPS), 60 and 78 days after transplantation, respectively. One patient with DLCL had a relapse on day 72 post transplant. Four patients received allogeneic stem cell transplantation, using unrelated donors (n ϭ 3) and a matched sibling (n ϭ 1). One unrelated recipient died of IPS on day 8 of the transplant. The second unrelated recipient with DLCL died of progressive disease on day 27. The three patients with IPS had received prior mediastinal irradiation before the current therapy. Currently, six patients are alive without evidence of disease, with a 3-year event-free survival rate of 40% (Figure 1a) . The 3-year event-free survival for the patients who underwent transplantation was 51% (Figure 1b) .
Discussion
As proof of principle, the present study shows that active chemotherapeutic agents can be dose-intensified and combined for salvage chemotherapy for patients with refractory lymphoma. The MTD of both ifosfamide and mitoxantrone was identified in the current regimen that made use of blood stem cells to reduce dose-limiting pancytopenia. Ifosfamide at 11.25 g/m 2 (3.75 g/m 2 ϫ 3 days) and mitoxantrone at 16 mg/m 2 in combination with other agents were tolerated well, albeit a further increase in ifosfamide to 15 g/m 2 (5 g/m 2 /day ϫ 3 days) resulted in two episodes of dose limiting toxicity. The dose of mitoxantrone was not escalated further from the baseline dose of 16 mg/m 2 due to the study scheme. Although renal failure may have been triggered or . [17] [18] [19] One other episode of DLT occurred as fatal septic pneumonia with Staphylococcus aureus during neutropenia despite the use of growth factor-primed stem cells. It remains to be seen whether the regimen increases the likelihood of infection during neutropenia because of the combination of high-dose methylprednisolone with mucolytic agents, ie Ara-C and mitoxantrone.
The three fatal cases of IPS post transplant may have been related to prior chest/mediastinal irradiation, 20 the current study regimen, transplant regimens or a combination of these treatments. Although the high dose of BCNU (600 mg/m 2 ) in the BVAC regimen and TBI of 1200 cGy and BCNU of 300 mg/m 2 of the TBI-BVAC regimen must have contributed to the lung injury, 21, 22 a careful prospective phase II study is necessary to elucidate the extent of pulmonary toxicity of the present study.
The response rate of 66% of the present study is encouraging, comparing favorably with published phase II studies, although it requires further study since it was a phase I investigation and there was a potential selection bias such as exclusion of patients who had evidence of disease in marrow or blood. 7, [22] [23] [24] [25] Although a number of phase II studies have shown that high-dose ablative therapy with stem cell transplantation was effective in patients with disease sensitive to pre-transplant salvage therapy, [1] [2] [3] [4] [5] [6] [7] 26 patients with resistant lymphoma, particularly those with primary refractory disease, have poor survival rates. 6, 7, 27, 28 In these patients, sensitivity of the tumor may have been reduced to below the 4-log kill with standard dose, which may not allow cure by a three-to five-fold increase in dose in the majority of patients, typically used in stem cell transplantation. 29 Similar to previous reports, the current study suggests that patients with refractory disease that is partially sensitive, could respond better to therapy with higher dose intensity than that used in the conventional salvage treatment, probably by achieving a higher log kill than standard salvage therapy. 30, 31 Responding patients would then be able to undergo stem cell transplantation with intent for cure by reducing tumor cells further to more than a 4-log overall tumor kill.
Our preliminary study lends support for further investigation of a dose-intensive approach for patients with primary refractory lymphoma. Questions that need to be answered are what chemotherapeutic agents and what combinations are best suited to this approach, how toxicity could be reduced and what sequence of therapy would be most appropriate. Since there may not be a further survival benefit from high dose of BCNU at 600 mg/m 2 or by TBI containing regimen, as suggested by previous transplant studies, patients who have received a significant amount of chest or mediastinal radiation may require an ablative regimen with a reduced dose of BCNU or non-TBI-based regimens for transplantation, to prevent IPS post-transplant. A phase II study of the present regimen is currently underway, which will provide an answer concerning its contribution to an overall survival benefit in patients with refractory lymphoma.
